A recent first-in-human trial using the EGFR antibody cetuximab conjugated to the near-infrared (NIR) fluorescent dye IRDye800 (cetuximab-IRDye800) during neurosurgical resection of gliomas demonstrated the specificity of the antibody-dye conjugate to specifically attach to EGFR-expressing glioma cells in the brain, enhancing the detection of tumor cells during surgery and potentially assisting the neurosurgeon in achieving a more extensive surgical resection, which could improve patient survival (Miller et al., 2018). This evidence concerns the gene EGFR and neoplasm.